The share price has tracked EPS growth, suggesting market sentiment towards the shares remains steady. The stock's recent performance has improved, with a better one-year total shareholder return than the five-year return. Dividends have enhanced the total shareholder return.
CSL anticipates robust annualized double-digit earnings growth over the medium term, driven by strong patient demand for its immunoglobulins franchise. The company has bounced back from the pandemic's impact on its blood plasma collections.
The positive trends in Carlisle Companies' ROCE and its ability to consistently reinvest in itself make it an attractive investment. Investors are expecting more growth in the future. However, it's important to check if these trends will continue.
The stock is seen as overpriced by valuation models, making it less attractive for purchase. With the company's low likelihood of significant earnings growth, its investment appeal is diminished. Profits could be made if share prices meet realistic values.
Carlisle Companies' growth is praised, but future performance remains key. Dividends have boosted total shareholder return, despite short-term performance being below market. Effective business strategy is expected to continue but investors should note identified risks.
Despite no insider trades recently at Carlisle Companies, management's considerable stock ownership aligns their interests with shareholders'. Yet, no insider buying in the last year is concerning.
This downgrade hints at a downturn in business conditions for Carlisle Companies, suggesting worse than industry performance and potential market caution. The downgrade may increase the company's debt pressure, hinting at possible fiscal tightening.
卡萊爾夥伴股票討論區
專欄US Top Gap Ups and Downs on 10/28: PINS, TMUS, AMZN, JD and More
Gap Ups
1. $德康醫療(DXCM.US)$ - up 6.43%
2. $艾奇資本(ACGL.US)$ - up 6.26%
3. $Pinterest(PINS.US)$ - up 5.32%
4. $吉利德科學(GILD.US)$ - up 3.83%
5. $威瑞信(VRSN.US)$ - up 3.65%
6. $T-Mobile US(TMUS.US)$ - up 3.05%
7. $亞瑟加拉格爾(AJG.US)$ - up 2.11%
8. $nVent Electric(NVT.US)$ - 2.09%...
卡萊爾夥伴(CSL)是1960年上市的美國公司,2002年到現在,股價從13.5上升到288,考慮到期間還做過一次1拆2,20年平均回報率20.6%,非常了得。
5年來毛利率在28%上下,淨資產收益率一度衝上23.8%,大部分時間都在18%以下,2021年為16.3%,沒有特別吸引人。
5年來營收從41億上升到48億,其中2020年下滑了11.8%;營業利潤在2019年到達高點,2020年下滑26%,2021年反彈17.4%;淨利潤在2018年達到高點,應該是有主營業務以外的收入,2019年恢復正常,2020年下滑32.3%,2021年又反彈了31.7%,5年總體還是提升的。
2022前兩季度營收、營業利潤和淨利潤分別暴增58%,215%,227%。
利潤表顯示2018年有2.5億的停止經營利潤,如果不考慮這部分,2018年淨利潤也是下滑的。5年來公司的利息費用不降反升,説明對借貸的依賴沒有減少。
資產負債表5年來從52.3%上升到了62%,主要是長期借款增加很快。另外2021年商譽及其他無形資產增加了15億,應該是有大筆收購...
專欄Top upgrades and downgrades on 4/5
• $Clean Harbors(CLH.US)$ : Goldman Sachs Upgrades to Neutral from Sell - PT $120
• $艾茨克普(EZPW.US)$ : Jefferies Upgrades to Buy From Hold - PT $8.50
• $First Republic Bank(FRC.US)$ : Credit Suisse Upgrades to Neutral From Underperform - PT $187
• $Generac(GNRC.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $410
• $梯瓦製藥(TEVA.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $13 (from $11)
• $賽萊默(XYL.US)$ ...
暫無評論